These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Visceral leishmaniasis in a patient with relapsed multiple myeloma receiving high-dose melphalan and autologous stem cell transplant. Radujkovic A; Hundemer M; Eisenbach C; Luft T; Penzel R; Goldschmidt H; Ho AD; Bellos F Leuk Lymphoma; 2014 Dec; 55(12):2967-9. PubMed ID: 24707945 [No Abstract] [Full Text] [Related]
4. Transformed essential thrombocytosis with a JAK2 V617F mutation relapsing as JAK2 mutation-negative leukaemia after allogeneic stem cell transplantation. Au WY; Fung A; Lam KY; Lie AK; Liang R; Kwong YL Bone Marrow Transplant; 2006 Oct; 38(8):573-4. PubMed ID: 16953212 [No Abstract] [Full Text] [Related]
5. Management of femoral fracture in a patient with essential thrombocythemia treated with plateletpheresis and intramedullary rod fixation, followed by hydroxyurea: a case report. Edlich RF; Long WB; Cochran AA; Kelley AR; Woode DR; Greene JA; Takahashi GW Am J Emerg Med; 2008 Jun; 26(5):636.e1-3. PubMed ID: 18534315 [TBL] [Abstract][Full Text] [Related]
6. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera. Michiels JJ; Pich A; De Raeve H; Gadisseur A Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159 [No Abstract] [Full Text] [Related]
7. Autologous reconstitution leading to sustained JAK2-V617F negativity post allogeneic hematopoietic stem cell transplant in JAK2-V617F positive myelofibrosis. Torka P; Hahn T; Bertolo J; Liu H; Ross M; Paplham P; Jankowski A; Deeb G; Chen G; McCarthy P Bone Marrow Transplant; 2015 Nov; 50(11):1480-2. PubMed ID: 26214139 [No Abstract] [Full Text] [Related]
8. Whole blood harvested after granulocyte-colony stimulating factor (Neupogen) mobilization, and reinfused unprocessed after high-dose melphalan treatment, accelerates hematopoietic recovery in patients with multiple myeloma. Raina V; Sharma A; Kumar R; Bhargava M Cancer; 1996 Mar; 77(6):1073-8. PubMed ID: 8635126 [TBL] [Abstract][Full Text] [Related]
9. Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial. Gupta S; Zhou P; Hassoun H; Kewalramani T; Reich L; Costello S; Drake L; Klimek V; Dhodapkar M; Teruya-Feldstein J; Hedvat C; Kalakonda N; Fleisher M; Filippa D; Qin J; Nimer SD; Comenzo RL Bone Marrow Transplant; 2005 Mar; 35(5):441-7. PubMed ID: 15640822 [TBL] [Abstract][Full Text] [Related]
13. Allografting or autografting for myeloma. Rajkumar SV; Kyle RA N Engl J Med; 2007 Jun; 356(25):2646-8; author reply 2646-8. PubMed ID: 17600891 [No Abstract] [Full Text] [Related]
14. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F. Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702 [TBL] [Abstract][Full Text] [Related]
15. A phase I study of intravenous plerixafor following cyclophosphamide mobilization in patients with multiple myeloma. Krishnan AY; Wang S; Palmer JM; Tsai NC; Thomas SH; Htut M; Farol L; Forman SJ Leuk Lymphoma; 2014 Jan; 55(1):201-3. PubMed ID: 23573824 [No Abstract] [Full Text] [Related]
16. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma. Batlle M; Morgades M; Vives S; Ferrà C; Oriol A; Sancho JM; Xicoy B; Moreno M; Magallón L; Ribera JM Eur J Haematol; 2014 Dec; 93(6):487-91. PubMed ID: 24889275 [TBL] [Abstract][Full Text] [Related]